MedDataX Logo

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

NCT ID: NCT00680017

Last Updated: 2012-10-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia Kidney Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dyslipidemia Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ABT-335 plus rosuvastatin

ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks

Group Type EXPERIMENTAL

ABT-335 plus rosuvastatin

Intervention Type DRUG

ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks

Rosuvastatin

Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Group Type ACTIVE_COMPARATOR

Rosuvastatin

Intervention Type DRUG

Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABT-335 plus rosuvastatin

ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks

Intervention Type DRUG

Rosuvastatin

Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

fenofibric acid and rosuvastatin rosuvastatin, Crestor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dyslipidemic participants with Chronic Kidney Disease Stage 3
* For entry into the Treatment Phase (Visit 3), the participant satisfied the following laboratory criteria (measured at the Screening Visit\[s\]):

* Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal Disease formula (this includes a 10 percent variation in the upper limit of estimated glomerular filtration rate that was allowed for the enrollment of participants to account for variability in the creatinine assay).
* Fasting lipid results following greater than or equal to 12-hour fasting period:
* Triglycerides level greater than or equal to 150 mg/dL,
* High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and

Exclusion Criteria

* Participants with certain chronic or unstable medical conditions.
* Participants with unstable dose of medications or receiving coumarin anticoagulants, systemic cyclosporine, or certain other medications.
* Pregnant or lactating women, or women intending to become pregnant.
* Participants with diabetes mellitus that is poorly controlled.
* Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Torbjörn Lundström, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Site Reference ID/Investigator# 22521

Birmingham, Alabama, United States

Site Status

Site Reference ID/Investigator# 22478

Huntsville, Alabama, United States

Site Status

Site Reference ID/Investigator# 8365

Madison, Alabama, United States

Site Status

Site Reference ID/Investigator# 8416

Montgomery, Alabama, United States

Site Status

Site Reference ID/Investigator# 7869

Chula Vista, California, United States

Site Status

Site Reference ID/Investigator# 8435

Fountain Valley, California, United States

Site Status

Site Reference ID/Investigator# 22487

Lincoln, California, United States

Site Status

Site Reference ID/Investigator# 22426

Long Beach, California, United States

Site Status

Site Reference ID/Investigator# 8096

Los Angeles, California, United States

Site Status

Site Reference ID/Investigator# 22962

Norwalk, California, United States

Site Status

Site Reference ID/Investigator# 8311

Riverside, California, United States

Site Status

Site Reference ID/Investigator# 22816

Sacramento, California, United States

Site Status

Site Reference ID/Investigator# 8510

Simi Valley, California, United States

Site Status

Site Reference ID/Investigator# 22821

West Hills, California, United States

Site Status

Site Reference ID/Investigator# 7958

Arvada, Colorado, United States

Site Status

Site Reference ID/Investigator# 15881

Denver, Colorado, United States

Site Status

Site Reference ID/Investigator# 8399

Westminster, Colorado, United States

Site Status

Site Reference ID/Investigator# 23224

Boynton Beach, Florida, United States

Site Status

Site Reference ID/Investigator# 22474

Clearwater, Florida, United States

Site Status

Site Reference ID/Investigator# 21803

Coral Springs, Florida, United States

Site Status

Site Reference ID/Investigator# 22811

Daytona Beach, Florida, United States

Site Status

Site Reference ID/Investigator# 27103

Hollywood, Florida, United States

Site Status

Site Reference ID/Investigator# 8398

Hudson, Florida, United States

Site Status

Site Reference ID/Investigator# 26723

Kissimmee, Florida, United States

Site Status

Site Reference ID/Investigator# 37676

Kissimmee, Florida, United States

Site Status

Site Reference ID/Investigator# 8231

Lauderdale Lakes, Florida, United States

Site Status

Site Reference ID/Investigator# 22486

Longwood, Florida, United States

Site Status

Site Reference ID/Investigator# 22520

New Port Richey, Florida, United States

Site Status

Site Reference ID/Investigator# 8226

Orlando, Florida, United States

Site Status

Site Reference ID/Investigator# 22477

Ormond Beach, Florida, United States

Site Status

Site Reference ID/Investigator# 8386

Pembroke Pines, Florida, United States

Site Status

Site Reference ID/Investigator# 22518

Plant City, Florida, United States

Site Status

Site Reference ID/Investigator# 12882

Port Charlotte, Florida, United States

Site Status

Site Reference ID/Investigator# 37675

Saint Cloud, Florida, United States

Site Status

Site Reference ID/Investigator# 8410

West Palm Beach, Florida, United States

Site Status

Site Reference ID/Investigator# 21802

Winter Haven, Florida, United States

Site Status

Site Reference ID/Investigator# 8136

Atlanta, Georgia, United States

Site Status

Site Reference ID/Investigator# 23503

Dunwoody, Georgia, United States

Site Status

Site Reference ID/Investigator# 7948

Macon, Georgia, United States

Site Status

Site Reference ID/Investigator# 22819

Roswell, Georgia, United States

Site Status

Site Reference ID/Investigator# 22813

Suwanee, Georgia, United States

Site Status

Site Reference ID/Investigator# 27682

Chicago, Illinois, United States

Site Status

Site Reference ID/Investigator# 8227

Peoria, Illinois, United States

Site Status

Site Reference ID/Investigator# 13922

Mishawaka, Indiana, United States

Site Status

Site Reference ID/Investigator# 8094

Council Bluffs, Iowa, United States

Site Status

Site Reference ID/Investigator# 22430

Iowa City, Iowa, United States

Site Status

Site Reference ID/Investigator# 8093

Paducah, Kentucky, United States

Site Status

Site Reference ID/Investigator# 38405

Baton Rouge, Louisiana, United States

Site Status

Site Reference ID/Investigator# 8903

Shreveport, Louisiana, United States

Site Status

Site Reference ID/Investigator# 21805

Auburn, Maine, United States

Site Status

Site Reference ID/Investigator# 8092

Rockville, Maryland, United States

Site Status

Site Reference ID/Investigator# 8225

Fall River, Massachusetts, United States

Site Status

Site Reference ID/Investigator# 8407

Springfield, Massachusetts, United States

Site Status

Site Reference ID/Investigator# 8415

Royal Oak, Michigan, United States

Site Status

Site Reference ID/Investigator# 22222

Brooklyn Center, Minnesota, United States

Site Status

Site Reference ID/Investigator# 8408

Olive Branch, Mississippi, United States

Site Status

Site Reference ID/Investigator# 22703

Berlin, New Jersey, United States

Site Status

Site Reference ID/Investigator# 22707

Elizabeth, New Jersey, United States

Site Status

Site Reference ID/Investigator# 22702

Hillsborough, New Jersey, United States

Site Status

Site Reference ID/Investigator# 8387

Flushing, New York, United States

Site Status

Site Reference ID/Investigator# 8177

Great Neck, New York, United States

Site Status

Site Reference ID/Investigator# 8146

Lake Success, New York, United States

Site Status

Site Reference ID/Investigator# 22427

Williamsville, New York, United States

Site Status

Site Reference ID/Investigator# 22481

Charlotte, North Carolina, United States

Site Status

Site Reference ID/Investigator# 22708

Charlotte, North Carolina, United States

Site Status

Site Reference ID/Investigator# 8434

Morehead City, North Carolina, United States

Site Status

Site Reference ID/Investigator# 8417

Cincinnati, Ohio, United States

Site Status

Site Reference ID/Investigator# 8147

Columbus, Ohio, United States

Site Status

Site Reference ID/Investigator# 22488

Mason, Ohio, United States

Site Status

Site Reference ID/Investigator# 22479

Oklahoma City, Oklahoma, United States

Site Status

Site Reference ID/Investigator# 23225

Oklahoma City, Oklahoma, United States

Site Status

Site Reference ID/Investigator# 22482

Tulsa, Oklahoma, United States

Site Status

Site Reference ID/Investigator# 8345

Bend, Oregon, United States

Site Status

Site Reference ID/Investigator# 22704

Medford, Oregon, United States

Site Status

Site Reference ID/Investigator# 8400

Portland, Oregon, United States

Site Status

Site Reference ID/Investigator# 8411

Bethlehem, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 8405

Carlisle, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 22387

Duncansville, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 22815

Jersey Shore, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 12881

Johnstown, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 22706

Perkasie, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 8095

Philadelphia, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 22705

Tipton, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 22817

Warminster, Pennsylvania, United States

Site Status

Site Reference ID/Investigator# 8098

Providence, Rhode Island, United States

Site Status

Site Reference ID/Investigator# 22823

Charleston, South Carolina, United States

Site Status

Site Reference ID/Investigator# 8364

Columbia, South Carolina, United States

Site Status

Site Reference ID/Investigator# 22429

Greenville, South Carolina, United States

Site Status

Site Reference ID/Investigator# 22428

Mt. Pleasant, South Carolina, United States

Site Status

Site Reference ID/Investigator# 25302

Summerville, South Carolina, United States

Site Status

Site Reference ID/Investigator# 22812

Dallas, Texas, United States

Site Status

Site Reference ID/Investigator# 8536

Edinburg, Texas, United States

Site Status

Site Reference ID/Investigator# 22810

Fort Worth, Texas, United States

Site Status

Site Reference ID/Investigator# 24742

Houston, Texas, United States

Site Status

Site Reference ID/Investigator# 26722

Houston, Texas, United States

Site Status

Site Reference ID/Investigator# 8406

Houston, Texas, United States

Site Status

Site Reference ID/Investigator# 8232

Lubbock, Texas, United States

Site Status

Site Reference ID/Investigator# 22480

San Antonio, Texas, United States

Site Status

Site Reference ID/Investigator# 8397

San Antonio, Texas, United States

Site Status

Site Reference ID/Investigator# 21804

Ogden, Utah, United States

Site Status

Site Reference ID/Investigator# 22423

Salt Lake City, Utah, United States

Site Status

Site Reference ID/Investigator# 8413

Gig Harbor, Washington, United States

Site Status

Site Reference ID/Investigator# 24402

Carolina, , Puerto Rico

Site Status

Site Reference ID/Investigator# 22545

Humacao, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8301

Manatí, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8299

Ponce, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8418

Ponce, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8419

Ponce, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8421

San Juan, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8300

San Juan, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8422

San Juan, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8423

San Juan, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8420

Toa Baja, , Puerto Rico

Site Status

Site Reference ID/Investigator# 8298

Yabucoa, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.

Reference Type DERIVED
PMID: 38018702 (View on PubMed)

Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clin Ther. 2013 Aug;35(8):1186-98. doi: 10.1016/j.clinthera.2013.06.013. Epub 2013 Jul 26.

Reference Type DERIVED
PMID: 23891363 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

M10-313

Identifier Type: -

Identifier Source: org_study_id